These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 16750175)

  • 1. Single amino acid residue determinants of non-peptide antagonist binding to the corticotropin-releasing factor1 (CRF1) receptor.
    Hoare SR; Brown BT; Santos MA; Malany S; Betz SF; Grigoriadis DE
    Biochem Pharmacol; 2006 Jul; 72(2):244-55. PubMed ID: 16750175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, G-protein-coupling sensitivity and determinants of CRF2 receptor selectivity.
    Hoare SR; Sullivan SK; Fan J; Khongsaly K; Grigoriadis DE
    Peptides; 2005 Mar; 26(3):457-70. PubMed ID: 15652653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
    Hoare SR; Sullivan SK; Schwarz DA; Ling N; Vale WW; Crowe PD; Grigoriadis DE
    Biochemistry; 2004 Apr; 43(13):3996-4011. PubMed ID: 15049707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding differences of human and amphibian corticotropin-releasing factor type 1 (CRF(1)) receptors: identification of amino acids mediating high-affinity astressin binding and functional antagonism.
    Dautzenberg FM; Wille S
    Regul Pept; 2004 May; 118(3):165-73. PubMed ID: 15003833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alanine scanning mutagenesis of the second extracellular loop of type 1 corticotropin-releasing factor receptor revealed residues critical for peptide binding.
    Gkountelias K; Tselios T; Venihaki M; Deraos G; Lazaridis I; Rassouli O; Gravanis A; Liapakis G
    Mol Pharmacol; 2009 Apr; 75(4):793-800. PubMed ID: 19124613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular interactions of nonpeptide agonists and antagonists with the melanocortin-4 receptor.
    Fleck BA; Chen C; Yang W; Huntley R; Markison S; Nickolls SA; Foster AC; Hoare SR
    Biochemistry; 2005 Nov; 44(44):14494-508. PubMed ID: 16262250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single amino acid of the cholecystokinin-B/gastrin receptor determines specificity for non-peptide antagonists.
    Beinborn M; Lee YM; McBride EW; Quinn SM; Kopin AS
    Nature; 1993 Mar; 362(6418):348-50. PubMed ID: 8455720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of N-terminal domains for corticotropin-releasing factor (CRF) receptor-ligand interactions.
    Klose J; Fechner K; Beyermann M; Krause E; Wendt N; Bienert M; Rudolph R; Rothemund S
    Biochemistry; 2005 Feb; 44(5):1614-23. PubMed ID: 15683245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monkey corticotropin-releasing factor1 receptor: Complementary DNA cloning and pharmacological characterization.
    Oshida Y; Ikeda Y; Chaki S; Okuyama S
    Life Sci; 2004 Feb; 74(15):1911-24. PubMed ID: 14761672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dihydropyridopyrazinones and dihydropteridinones as corticotropin-releasing factor-1 receptor antagonists: structure-activity relationships and computational modeling.
    Dzierba CD; Tebben AJ; Wilde RG; Takvorian AG; Rafalski M; Kasireddy-Polam P; Klaczkiewicz JD; Pechulis AD; Davis AL; Sweet MP; Woo AM; Yang Z; Ebeltoft SM; Molski TF; Zhang G; Zaczek RC; Trainor GL; Combs AP; Gilligan PJ
    J Med Chem; 2007 May; 50(9):2269-72. PubMed ID: 17402721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-amino acid motifs of urocortin II and III determine their CRF receptor subtype selectivity.
    Jahn O; Tezval H; van Werven L; Eckart K; Spiess J
    Neuropharmacology; 2004 Aug; 47(2):233-42. PubMed ID: 15223302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allosteric ligands for the corticotropin releasing factor type 1 receptor modulate conformational states involved in receptor activation.
    Hoare SR; Fleck BA; Gross RS; Crowe PD; Williams JP; Grigoriadis DE
    Mol Pharmacol; 2008 May; 73(5):1371-80. PubMed ID: 18239030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relaxin-3, INSL5, and their receptors.
    Liu C; Lovenberg TW
    Results Probl Cell Differ; 2008; 46():213-37. PubMed ID: 18236022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The three-dimensional structure of the N-terminal domain of corticotropin-releasing factor receptors: sushi domains and the B1 family of G protein-coupled receptors.
    Perrin MH; Grace CR; Riek R; Vale WW
    Ann N Y Acad Sci; 2006 Jul; 1070():105-19. PubMed ID: 16888152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracellular cysteines of the corticotropin-releasing factor receptor are critical for ligand interaction.
    Qi LJ; Leung AT; Xiong Y; Marx KA; Abou-Samra AB
    Biochemistry; 1997 Oct; 36(41):12442-8. PubMed ID: 9376348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding kinetics redefine the antagonist pharmacology of the corticotropin-releasing factor type 1 receptor.
    Fleck BA; Hoare SR; Pick RR; Bradbury MJ; Grigoriadis DE
    J Pharmacol Exp Ther; 2012 May; 341(2):518-31. PubMed ID: 22357972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular determinants of melanocortin 4 receptor ligand binding and MC4/MC3 receptor selectivity.
    Nickolls SA; Cismowski MI; Wang X; Wolff M; Conlon PJ; Maki RA
    J Pharmacol Exp Ther; 2003 Mar; 304(3):1217-27. PubMed ID: 12604699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of NBI-77860/GSK561679, a potent corticotropin-releasing factor (CRF1) receptor antagonist with improved pharmacokinetic properties.
    Tellew JE; Lanier M; Moorjani M; Lin E; Luo Z; Slee DH; Zhang X; Hoare SR; Grigoriadis DE; St Denis Y; Di Fabio R; Di Modugno E; Saunders J; Williams JP
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7259-64. PubMed ID: 21074436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping the binding site of six nonpeptide antagonists to the human V2-renal vasopressin receptor.
    Macion-Dazard R; Callahan N; Xu Z; Wu N; Thibonnier M; Shoham M
    J Pharmacol Exp Ther; 2006 Feb; 316(2):564-71. PubMed ID: 16234409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct conformations of the corticotropin releasing factor type 1 receptor adopted following agonist and antagonist binding are differentially regulated.
    Perry SJ; Junger S; Kohout TA; Hoare SR; Struthers RS; Grigoriadis DE; Maki RA
    J Biol Chem; 2005 Mar; 280(12):11560-8. PubMed ID: 15653688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.